The circulating senosome: Blood as the therapeutic interface of aging.
Key claim: Aging is communicated systemically through a composite blood-borne network of senescence, inflammatory, metabolic, microbial, and nucleic-acid mediators—the circulating senosome—making blood both a biomarker compartment and a therapeutic interface for geroscience.
Abstract
Aging is commonly framed as a progressive accumulation of cellular and tissue-level damage. However, the aged organism does not decline as a collection of isolated organs. Aging is communicated systemically through blood-borne signals that connect senescent cells, immune remodeling, vascular dysfunction, metabolic stress, dysbiosis, and chronic inflammation. I propose the concept of the circulating senosome to describe the composite network of age-associated circulating mediators, including senescence-associated secretory phenotype proteins, extracellular vesicles, inflammatory cytokines, lipids, metabolites, complement and coagulation mediators, autoantibodies, cell-free nucleic acids, and microbiome-derived products. This framework positions blood as both a biomarker compartment and a therapeutic interface in aging biology. The circulating senosome does not replace established hallmarks of aging; rather, it provides a systemic layer through which multiple hallmarks interact. Defining, measuring, and therapeutically remodeling this circulating network may create new opportunities for translational geroscience.
Why this matters
This review attempts to collapse several previously parallel conversations — SASP, inflammaging, EVs, microbial metabolites, cfDNA, complement — into a single composite called the circulating senosome, with blood as the measurement and therapeutic interface. The reframing matters for mechanism pages because it reorganizes how systemic aging signals should be catalogued and quantified, and it foreshadows a wave of multi-analyte ‘senosome score’ biomarkers and plasma-targeted therapeutics. The gap to watch is whether composite-score narratives outrun the component-level causal evidence, which remains preclinical for most listed mediators.